These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 22145213)

  • 1. [Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].
    Fabian P; Berkovcová J
    Cesk Patol; 2011 Oct; 47(4):154-8. PubMed ID: 22145213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
    Siena S; Sartore-Bianchi A; Di Nicolantonio F; Balfour J; Bardelli A
    J Natl Cancer Inst; 2009 Oct; 101(19):1308-24. PubMed ID: 19738166
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    van Brummelen EMJ; de Boer A; Beijnen JH; Schellens JHM
    Oncologist; 2017 Jul; 22(7):864-872. PubMed ID: 28576857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant.
    Molinari F; Martin V; Saletti P; De Dosso S; Spitale A; Camponovo A; Bordoni A; Crippa S; Mazzucchelli L; Frattini M
    Br J Cancer; 2009 Apr; 100(7):1087-94. PubMed ID: 19293803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab.
    Smith CG; Fisher D; Claes B; Maughan TS; Idziaszczyk S; Peuteman G; Harris R; James MD; Meade A; Jasani B; Adams RA; Kenny S; Kaplan R; Lambrechts D; Cheadle JP
    Clin Cancer Res; 2013 Aug; 19(15):4104-13. PubMed ID: 23741067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    Lu X; Li Y; Li Y; Zhang X; Shi J; Feng H; Yu Z; Gao Y
    BMC Cancer; 2023 Nov; 23(1):1117. PubMed ID: 37974093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development.
    Eng C
    Oncologist; 2010; 15(1):73-84. PubMed ID: 20067946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer.
    Sforza V; Martinelli E; Ciardiello F; Gambardella V; Napolitano S; Martini G; Della Corte C; Cardone C; Ferrara ML; Reginelli A; Liguori G; Belli G; Troiani T
    World J Gastroenterol; 2016 Jul; 22(28):6345-61. PubMed ID: 27605871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas.
    Raghav KP; Shetty AV; Kazmi SM; Zhang N; Morris J; Taggart M; Fournier K; Royal R; Mansfield P; Eng C; Wolff RA; Overman MJ
    Oncologist; 2013; 18(12):1270-7. PubMed ID: 24149137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer.
    De Stefano A; Carlomagno C
    World J Gastroenterol; 2014 Aug; 20(29):9732-43. PubMed ID: 25110411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer.
    Di Fiore F; Sesboüé R; Michel P; Sabourin JC; Frebourg T
    Br J Cancer; 2010 Dec; 103(12):1765-72. PubMed ID: 21139621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients.
    Lupini L; Bassi C; Mlcochova J; Musa G; Russo M; Vychytilova-Faltejskova P; Svoboda M; Sabbioni S; Nemecek R; Slaby O; Negrini M
    BMC Cancer; 2015 Oct; 15():808. PubMed ID: 26508446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer.
    Yang L; Bhattacharya A; Li Y; Sexton S; Ling X; Li F; Zhang Y
    J Exp Clin Cancer Res; 2022 Jun; 41(1):184. PubMed ID: 35650607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice.
    Blanke CD; Goldberg RM; Grothey A; Mooney M; Roach N; Saltz LB; Welch JJ; Wood WA; Meropol NJ;
    Oncologist; 2011; 16(8):1061-8. PubMed ID: 21737577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case report outcome of cetuximab treatment in a metastatic colorectal cancer patient with novel KRAS P34R.
    Chen R; Yang D; Liu Y; Wang B; Xu H
    Anticancer Drugs; 2024 Feb; 35(2):195-198. PubMed ID: 38018809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular alterations and biomarkers in colorectal cancer.
    Grady WM; Pritchard CC
    Toxicol Pathol; 2014 Jan; 42(1):124-39. PubMed ID: 24178577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution.
    Khan K; Valeri N; Dearman C; Rao S; Watkins D; Starling N; Chau I; Cunningham D
    Crit Rev Oncol Hematol; 2019 Nov; 143():153-163. PubMed ID: 31678702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming the hurdles: surmounting acquired resistance to anti-EGFR therapy in metastatic colorectal cancer.
    Sackstein PE; Chintapally N; Wilgucki M; Hartley ML; Alqahtani A; Weinberg BA
    Clin Adv Hematol Oncol; 2023 Nov; 21(11):572-583. PubMed ID: 37948593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells.
    Landi N; Ciaramella V; Ragucci S; Chambery A; Ciardiello F; Pedone PV; Troiani T; Di Maro A
    Toxins (Basel); 2023 Jan; 15(1):. PubMed ID: 36668877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer.
    Lin JS; Webber EM; Senger CA; Holmes RS; Whitlock EP
    Am J Cancer Res; 2011 May; 1(5):650-62. PubMed ID: 21779535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.